MET and endometrial cancer: To focus on therapeutically targetable fusion transcripts in endometrial cancer, from the initial list of 124 fusion transcripts, we identified three in-frame kinase fusion transcripts (CPQ-PRKDC, VGLL4-PRKG1, and CAPZA2-MET) that were supported by more than 10 junction-spanning reads, which included an intact kinase domain (Fig. 3a)21.